Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Colorectal screening - Management
View full scenario

Why screen for bowel cancer?

  • Bowel cancer screening meets the criteria for a viable, effective, and appropriate screening programme. In particular:
    • Bowel cancer is an important health problem, causing approximately 16,000 deaths per year.
    • Bowel cancer may be detected at an asymptomatic stage by a simple, safe, and validated screening test that is generally acceptable to the population.
    • Early treatment of bowel cancer leads to better outcomes.
    • Bowel cancer screening can be be effectively implemented within the NHS.
Basis for recommendation

Criteria for a screening programme

  • The NHS Bowel Cancer Screening Programme meets the UK National Screening Committee criteria for a viable, effective, and appropriate screening programme based on [UK National Screening Committee, 2009]:
    • Evidence from three randomized controlled trials and a meta-analysis of the data from these trials that found screening reduces bowel cancer mortality by approximately 16% [Mandel et al, 1993; Hardcastle et al, 1996; Kronborg et al, 1996; Hewitson et al, 2007].
    • Evidence from one randomized controlled trial that found that screening reduces the incidence of bowel cancer in a screened population [Mandel et al, 2000]. This was presumed to occur because removal of benign polyps, identified by colonoscopy after an abnormal screening test, prevented their development into malignant lesions.
    • Evidence from an evaluation of the pilot of the Bowel Cancer Programme commissioned by the Department of Health that found a screening programme can be effectively implemented within the NHS [Weller et al, 2003; Weller et al, 2006].

Bowel cancer mortality

How is the screening test done?

  • A testing kit complete with full instructions (pdf) is sent out 1 week after an invitation for screening.
  • Two samples are collected from each of three separate bowel motions by the person at home, using the cardboard sticks provided.
  • One of three flaps on the testing kit is peeled back for each bowel motion. A sample is applied to each of the two exposed windows before resealing the window.
  • Once all six windows have been used the kit is returned for analysis.
  • The kit must be returned within 14 days of the first sample being taken.

[NHS Bowel Cancer Screening Programme, 2006]

What is an abnormal/normal screening test?

  • The result of a single screening test is considered to be:
    • Clearly normal if none of the six samples taken are positive for faecal occult blood.
    • Clearly abnormal if five or six of the samples taken are positive for faecal occult blood.
    • Unclear if one to four of the six samples taken are positive for faecal occult blood.
  • For people with a single unclear test result, up to two further tests may be required for clarification. Subsequently:
    • Screening is considered normal if:
      • The initial screening test is clearly normal, or
      • An initial screening test was unclear, but two subsequent screening tests are normal.
    • Screening is considered abnormal if:
      • The initial screening test is clearly abnormal, or
      • An initial screening test is unclear, and one of two subsequent screening tests is unclear or clearly abnormal.
  • If there is a technical problem in processing the kit or the kit is unreadable owing to incorrect use, participants are sent a letter explaining the problem and a replacement kit.

[NHS Bowel Cancer Screening Programme, 2006]

What is the significance of a normal/abnormal screening test?

People with an abnormal faecal occult blood test (FOBt) result

  • People with an abnormal FOBt result who have not previously been screened have approximately:
    • A 10% chance of having a bowel cancer, and
    • A 40% chance of having a benign polyp, which may progress to a malignant lesion if left untreated.
  • People with an abnormal FOBt result who had a normal FOBt result within the past 2 years have approximately:
    • A 5% chance of having a bowel cancer, and
    • A 25% chance of having a benign polyp, which may progress to a malignant lesion if left untreated.

People with a normal FOBt result

  • A proportion of people with a normal FOBt result will have bowel cancer, but the risk of cancer after a normal FOBt result is unknown because no studies have compared FOBt with a gold-standard investigation, such as colonoscopy, to accurately determine the specificity or negative predictive value of FOBt screening.

People with colorectal cancer

  • An estimated 60% of people with colorectal cancer will have an abnormal FOBt screening result.
Basis for recommendation

The significance of an abnormal faecal occult blood test (FOBt) result

  • For people with an abnormal FOBt result who have not previously been screened, the chance that they will have bowel cancer or a benign polyp is based on evidence from the first screening round of the UK Colorectal Cancer Screening Pilot [Weller et al, 2003].
  • For people with an abnormal FOBt who had a normal FOBt result within the past 2 years, the chance that they will have bowel cancer or a benign polyp is based on evidence from the second screening round of the english pilot of bowel cancer screening [Weller et al, 2006]. Approximately 80% of people in the second screening round had been screened in the first screening round. This data provides a rough estimate of the risk of cancer for people that have previously been screened.

Estimated sensitivity of FOBt

  • The estimated sensitivity of FOBt for detecting bowel cancer in people with the disease has been calculated from data from three good-quality randomized controlled trials in a Cochrane systematic review [Hewitson et al, 2007].
    • It was calculated from the number of people known to have had an abnormal FOBt result and an estimate of the true number of people with bowel cancer.
    • The true number of people with bowel cancer at the time of screening was estimated from the number of people with bowel cancer detected by screening plus the number of people who developed bowel cancer within 2 years of being screened.

What will happen following an abnormal screening test?

People with an abnormal screening result will be:

  • Sent a letter explaining the result, with an appointment at a nurse-run clinic within 1 week. A copy of this letter will be sent to the GP.
  • Offered colonoscopy; occasionally, other imaging techniques may be offered if colonoscopy is inappropriate.
    • People with a suspicious lesion should either have the lesion removed entirely or have sufficient biopsy samples taken to clearly determine the nature of the lesion.
      • If biopsy confirms colorectal cancer, the person will be seen at a nurse-run clinic to discuss the result face to face and referred urgently to a named specialist.
      • If biopsy confirms a benign lesion, the person will informed of the result by letter within 3 weeks.
    • People with benign polyps will usually have these removed. Polyps are classified into low, medium, or high risk depending on the number and size of polyps found.
      • People with low-risk polyps are offered further FOBt screening every 2 years, up until the age of 70 years.
      • People with medium-risk polyps are offered colonoscopy every 3 years until two examinations are negative.
      • People with high-risk polyps are offered repeat colonoscopy after 1 year and then colonoscopy every 3 years until two examinations are negative.
    • People with no abnormality detected by complete colonoscopy will be offered further FOBt screening every 2 years, until they are 70 years of age.
    • People with an incomplete colonoscopy due to technical difficulties may be offered repeat colonoscopy or another imaging technique.

[NHS Bowel Cancer Screening Programme, 2006]

What will happen following a normal screening test?

  • People with a normal screening result will:
    • Receive a letter explaining the result and information about the symptoms and signs of bowel cancer to look out for in the future.
    • Be offered further faecal occult blood test screening every 2 years, until they are 70 or 74 years of age, depending on the maximum age range being used in their area.

[NHS Bowel Cancer Screening Programme, 2006]

What are the possible harms of the screening programme?

  • Anxiety over false-positive screening results.
  • Complications of colonoscopy, including:
    • Heavy bleeding — occurs in approximately 1 in 600 people.
    • Bowel perforation — occurs in approximately 1 in 1200 people.
    • Death — occurs in approximately 1 in 14,000 people.
  • Inappropriate reassurance from a negative screening result may lead people to ignore symptoms of bowel cancer unless they understand the limitations of screening. To reduce the risk of this occurring:
    • Written information about the limitations of the screening test, and the symptoms of bowel cancer, is provided before the faecal occult blood test kit is sent.
    • Information about the symptoms of bowel cancer to be looked for is again provided when people are informed of a normal screening result.
Basis for recommendation

Complications of colonoscopy

  • The risk of complications from colonoscopy is based on evidence from an observational study of approximately 100,000 people 50–75 years of age undergoing colonoscopy that were representative of a colorectal screening population [Rabeneck et al, 2008].

The risk of screening causing anxiety or inappropriate reassurance

  • The risk of screening causing anxiety after an abnormal screening result or inappropriate reassurance after a normal screening result has not been formally studied but is considered a significant risk in the opinion of experts [Rhodes, 2000].

What information about screening is available for patients?

  • A patient information leaflet entitled Bowel cancer: the facts can be ordered or downloaded from the NHS cancer screening website. It is available in:
    • 20 languages.
    • An audio CD set.
    • British sign language.
    • A large print version.

© NHS Institute for Innovation and Improvement